An Open Label Phase 2 Feasibility Study to Assess the Safety and Efficacy of BPX-04 Minocycline Topical Gel in Treatment of Moderate to Severe Papulopustular Rosacea (BPX-01-C05)

Trial Profile

An Open Label Phase 2 Feasibility Study to Assess the Safety and Efficacy of BPX-04 Minocycline Topical Gel in Treatment of Moderate to Severe Papulopustular Rosacea (BPX-01-C05)

Active, no longer recruiting
Phase of Trial: Phase I/II

Latest Information Update: 29 May 2018

At a glance

  • Drugs Minocycline (Primary)
  • Indications Rosacea
  • Focus Therapeutic Use
  • Sponsors BioPharmX Corporation
  • Most Recent Events

    • 21 May 2018 Status changed from Recruiting to active, no longer recruiting.
    • 12 Jan 2018 According to a BioPharmX Corporation media release, data from the study will be presented at the Winter Clinical Dermatology Conference 2017.
    • 14 Dec 2017 Planned End Date changed from 1 Dec 2017 to 30 Jun 2018.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top